Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-10-03
2009-12-08
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C514S002600
Reexamination Certificate
active
07629136
ABSTRACT:
Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
REFERENCES:
patent: 5763223 (1998-06-01), Wiley et al.
patent: 6072047 (2000-06-01), Rauch et al.
patent: 6252050 (2001-06-01), Ashkenazi et al.
patent: 6284236 (2001-09-01), Wiley et al.
patent: 6313269 (2001-11-01), Deen et al.
patent: 6342383 (2002-01-01), Perron et al.
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 6569642 (2003-05-01), Rauch et al.
patent: 6642358 (2003-11-01), Rauch et al.
patent: 2001/0010924 (2001-08-01), Deen et al.
patent: 2002/0048785 (2002-04-01), Holtzman
patent: 2002/0072091 (2002-06-01), Ni et al.
patent: 2002/0098550 (2002-07-01), Ni et al.
patent: 2002/0160446 (2002-10-01), Holtzman
patent: 2003/0125554 (2003-07-01), Bernard et al.
patent: 2003/0133932 (2003-07-01), Zhou et al.
patent: 870827 (2004-03-01), None
patent: 97/01633 (1997-01-01), None
patent: 97/25428 (1997-07-01), None
patent: 98/32856 (1998-07-01), None
patent: 98/35986 (1998-08-01), None
patent: 98/41629 (1998-09-01), None
patent: WO 98/51793 (1998-11-01), None
patent: 99/02653 (1999-01-01), None
patent: 99/09165 (1999-02-01), None
patent: 99/11791 (1999-03-01), None
patent: 99/36535 (1999-07-01), None
patent: 99/37684 (1999-07-01), None
patent: WO 00/73349 (2000-12-01), None
patent: 01/00832 (2001-01-01), None
patent: 02/097033 (2002-12-01), None
patent: WO 03/037913 (2003-05-01), None
patent: WO 03/038043 (2003-05-01), None
patent: WO 03/042367 (2003-05-01), None
Togayachi et al, 1999, Int. J. Cancer vol. 83, pp. 70-79.
Science, 277:818-821 (1997).
Ashkenazi et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand”Journal of Clinical Investigation104(2) :155-162 (1999).
Ichikawa, K. et al., “Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity”Nature Med. 7(8) :954-960 (2001).
Matsumoto et al.Br. J. Cancer86(2) :161-167 (2002).
Ugorski et al.Acta Biochimica Polonica49(2) :303-311 (2002).
Walczak et al., “Tumoricidal activity of tumor necrosis factor-related apoptosis-including ligand in vivo”Nature Med. 5:157-163 (1999).
Akamatsu et al.Glycoconjugate Journal13:1021-1029 (1996).
Asao et al., “Serum alpha (1-3)-L-Fucosyltransferase, Carcinoembryonic Antigen, and Sialyl Lewis X-i Antigen Levels in Lung Cancer”Cancer64(12):2541-2545 (1989).
Ashizawa et al., “The clinical significance of sialyl Lewis antigen expression in the spread of gastric cancer. Flow cytometric DNA analysis”J. Exp. Clin Cancer Res.22(1):91-8 (2003).
Ashkenazi and Dixit., “Death Receptors: Signaling and Modulation.”Science. 281(5381):1305-1308 (1998).
Ashkenazi et al.Curr. Opin. Cell Biol. 11:255-260 (1999).
Ashkenazi et al., “Targeting death and decoy receptors of the tumour-necrosis factor superfamily”Nature Reviews—Cancer2:420-430 (2002).
Azuma et al., “Expression of cell surface Lewis X and Y antigents and FUT4 mRNA is increased in Jurkat cells undergoing apoptosis”Biochimica et Biophysica Acta1672(3):157-163 (2004).
Chuntharapai et al., “Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4”J. Immunol. 166:4891-4898 (2001).
Degli-Esposti et al., “Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family”Journal of Experimental Medicine186(7) :1165-1170 (1997).
Degli-Esposti et al., “The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain”Immunity7:813-820 (1997).
Dermer, G., “Another anniversry for the war on cancer”Biotechnology12:320 (1994).
Freshney, R.Culture of Animal Cells: A Manual of Basic Technique, New York:Alan R. Liss, Inc. pp. 3-4 (1983).
Fujii et al., “Significance of carbohydrate antigen sialyl-Lewis X, sialyl-Lewis A, and possible unknown ligands to adhesion of human urothelial cancer cells to activated endothelium”Urol Int. 64(3):129-33 (2000).
Fujiwara et al., “Lung Cancer Cell Line Producing Cytokeratin 19 Fragment and Sialyl Lewis X-i Antigen”Anticancer Research18(2A):1043-46 (1998).
Fukuoka et al., “Increased Expression of Sialyl Lewis(x) Antigen is associated with distant metastasis in lung cancer patients: Immunohistochemical Study on Bronchofiberscopic Biopsy Specimens”Lung Cancer20(2) :109-116 (1998).
Griffith et al., “Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies”The Journal of Immunology162:2597-2605 (1999).
Gura, T., “Systems for identifying new drugs are often faulty”Science278:1041-1042 (Nov. 7, 1997).
Hamanaka et al, “Sialyl Lewis(a) ganglioside in pnacreatic cancer tissue correlates with the serum CA 19-9 level”Pancreas. 13(2):160-5 (1996).
Ho et al., “Association of sialyl-Lewis(a) and sialyl-Lewis(x) with MUC-1 apomucin in a pancreatic cancer cell line”Cancer Research55(16):3659-63 (1995).
Hylander et al., “An antibody to DR5 (TRAIL-Receptor 2) suppresses the growth of patient derived gastrointestinal tumors grown in SCID mice.” (Abstract, 2d International Congress on Monoclonal Antibodies in Cancers, Aug. 29-Sep. 1, 2002, Banff, Canada).
Idikio, “Sialyl-lewis-X, Gleason grade and stage in non-metastatic human prostate cancer”Glycoconjugate Journal14:875-877 (1997).
Ikeda et al., “Immunohistochemical expression of sialyl Tn, sialyl Lewis a, sialyl Lewis a-b-, and sialyl Lewis x in primary tumor and metastatic lymph nodes in human gastric cancer”J Surg Oncol. 62(3):171-6 (1996).
Ikeda et al., “Immunohistochemical expression of sialyl Tn and sialyl Lewis(a) antigens in stromal tissue correlates with peritoneal dissemination in stage IV human gastric cancer”Eur J Surg Oncol21(2):168-75 (1995).
Inoue et al., “Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors”Obstet Gynecol. 79(3):434-440 (1992).
Ito et al., “Paired tumor marker of soluble E-selectin and its ligand sialyl Lewis A in colorectal cancer”J. Gastroenterology36(12):823-829 (2001).
Izawa et al, “Expression of Sialyl 6-Sulfo Lewis X Is Inversely Correlated with Conventional Sialyl Lewis X Expression in Human Colorectal Cancer”Cancer Research60:1410-1416 (2000).
Koszdin et al.Biochemical and Biophysical Research Communications187(1):152-157 (1992).
Kukowska-Latallo et al.Genes Dev. 4(8):1288-1303 (1990).
Kumamoto et al., “Increased Expression of UDP-Galactose Transporter Messenger RNA in Human Colon Cancer Tissues and Its Implication in Synthesis of Thomsen-Freidenreich Antigena nd Sialyl Lewis A/X determinants”Cancer Research61:4620-4627 (2001).
Li et al., “The expression of sialyl Lewis-X antigen in LoVo, HT29 cell lines of colorectal cancer and its correlation with metastatic potential”Zhonghua Bing Li Xue Za Zhi29(2):119-122 (2000).
Locksley et al., “The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology”Cell104:487-501 (Feb. 23, 2001).
MacFarlane et al.Journal of Biological Chemistry272:25417-25420 (1997).
Marsters et al., “A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain”Current Biology7:1003-1006 (1997).
Matsushita et al., “Selectins induced by interleukin-
Ashkenazi Avi J.
Wagner Klaus W.
Genentech Inc.
Marschang Diane L.
Yu Misook
LandOfFree
Assays and methods using biomarkers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assays and methods using biomarkers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assays and methods using biomarkers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4135061